Open AccessSalivary Alpha Amylase Enzyme and Salivary Cortisol Level in Depression after Treatment with Fluoxetine
Author(s) -
Andi Jayalangkara Tanra,
Hawaidah Madeali,
Mayamariska Sanusi,
Saidah Syamsuddin,
Sonny Teddy Lisal
Publication year - 2021
Publication title -
open access macedonian journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.288
H-Index - 17
ISSN - 1857-9655
DOI - 10.3889/oamjms.2021.6278
Subject(s) - fluoxetine , medicine , serotonin reuptake inhibitor , antidepressant , depression (economics) , endocrinology , biomarker , hydrocortisone , reuptake inhibitor , serotonin , receptor , biochemistry , chemistry , macroeconomics , hippocampus , economics
BACKGROUND: Hypothalamic-pituitary-adrenal axis and its end product cortisol have been extensively investigated in patients with depressive disorders for many years. Recently, salivary alpha-amylase (sAA) had emerged as a new biomarker with non-invasive and more convenience protocol for measuring sympathetic activity which were also associated with depression. Selective Serotonin Reuptake Inhibitor is antidepressant drug extensively used to treat depression.AIM: The aim of this study was to determine whether decrease of sAA and salivary cortisol levels could be observed in subjects with depression who were treated by fluoxetine.METHODS: The total subjects were 25 depressed subjects and ten healthy controls. sAA was examined before therapy, and after 2, 4, and 6 weeks of fluoxetine administration using a portable cocorometer. Salivary cortisol was examined before therapy, after 4 and 6 weeks of fluoxetine administration with Elisa method. The therapeutic effect was assessed with Hamilton Depression Rating Scale (HDRS).RESULTS: sAA and cortisol levels were significantly decreased after fluoxetine administration (p < 0.001), followed by at least 50% reduction of HDRS scores after 6 weeks of fluoxetine administration. Levels of sAA and cortisol were higher in the depression group than in the healthy control.CONCLUSIONS: Measurement of sAA levels can be used as a potential biomarker of therapeutic response in depressed patients in addition to salivary cortisol.